=> d l17
L17 HAS NO ANSWERS
L17 STR




REP G1=(0-7) CH2
VAR G2=O/S
VAR G3=9/8/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 5 2
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s l17 ful
FULL SEARCH INITIATED 12:41:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20046 TO ITERATE

100.0% PROCESSED 20046 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L19 0 SEA SSS FUL L17

```
> d l23
L23 HAS NO ANSWERS
L23                STR
```




```
REP G1=(0-7) CH2
VAR G2=O/S
VAR G3=9/8/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   5   1
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE


=> s l23 ful
FULL SEARCH INITIATED 12:42:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  20046 TO ITERATE

100.0% PROCESSED   20046 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L24            0 SEA SSS FUL L23

=>
```

=> d l25
L25 HAS NO ANSWERS
L25 STR




REP G1=(0-7) CH2
VAR G2=O/S
VAR G3=9/8/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 5 3
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s l25 ful
FULL SEARCH INITIATED 12:44:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 24727 TO ITERATE

100.0% PROCESSED 24727 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

L27 20 SEA SSS FUL.L25

=> fil caplus
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 627.98 | 628.19 |

FILE 'CAPLUS' ENTERED AT 12:44:06 ON 26 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 26 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 25 May 2004 (20040525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l27
L28           1 L27

=> d bib abs

L28  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:31042  CAPLUS
DN   136:85625
TI   1,1- and 1,2-disubstituted cyclopropanes, process for their preparation
     and pharmaceutical compositions thereof
IN   Goldstein, Solo; Guillonneau, Claude; Charton, Yves; Lockhart, Brian;
     Lestage, Pierre
PA   Les Laboratoires Servier, Fr.
SO   Eur. Pat. Appl., 49 pp.
     CODEN: EPXXDW
DT   Patent
LA   French
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   EP 1170281          A1   20020109       EP 2001-401677   20010626
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
     FR 2810664          A1   20011228       FR 2000-8203     20000627
     JP 2002069046       A2   20020308       JP 2001-191541   20010625
     NO 2001003206       A    20011228       NO 2001-3206     20010626
     US 2002022643       A1   20020221       US 2001-888990   20010626
     CN 1330067          A    20020109       CN 2001-121831   20010627
     ZA 2001005300       A    20020111       ZA 2001-5300     20010627
     BR 2001002587       A    20020528       BR 2001-2587     20010627
PRAI FR 2000-8203        A    20000627
OS   CASREACT 136:85625; MARPAT 136:85625
GI
```




I


AB   Compds. I [Z = (CH2)p; p = 0 - 6; n = 0 - 6; R1, R2 = H, linear or branched C1-6-alkyl, aryl, linear or branched C1-6-arylalkyl; R1R2N = saturated mono- or bicyclic 3 - 10 membered ring with an optional O, s or second N; X = O, S, CH:CH, CH2, HC:NO, OCH2CH:CH; Y = aryl, heteroaryl, linear or branched C1-6-arylalkyl, C1-6-heteroarylalkyl, C(:O)A, C(:S)A; A = linear or branched C1-6-alkyl, aryl, heteroaryl, linear or branched C1-6-arylalkyl, NR3R4; R3, R4 = H, linear or branched C1-6-alkyl, aryl, linear or branched C1-6-arylalkyl; R3R4N = saturated mono- or bicyclic 3 - 10 membered ring] their optical isomers and their pharmaceutically acceptable salts are useful for treatment of memory associated diseases. Thus, (±)-cis-2-(dimethylamino)cyclopropyl acetate was prepared from 2-(vinyloxy)tetrahydropyran over 9 steps via a rhodium-catalyzed cyclopropanation. I were tested for nicotinic (Ki = 10 - 100 nM for α4β2) and muscarinic (Ki = 10 μM) receptor binding.


```
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

AN 2001:780887 CAPLUS
DN 135:331414
TI Benzo[h][1,6]naphthyridine and azepino[3,2c]quinoline imino-ethers, preparation method, and therapeutic use thereof as 5-HT4 receptor antagonists
IN Rault, Sylvain; Hinschberger, Antoine; Dauphin, Francois; Boulouard, Michel; Dumuis, Aline
PA Universite de Caen Basse-Normandie, Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001079205 | A1 | 20011025 | WO 2001-FR1114 | 20010411 |
| | W: CA, JP, NO, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| | FR 2807755 | A1 | 20011019 | FR 2000-4811 | 20000414 |
| | FR 2807755 | B1 | 20020809 | | |
| PRAI | FR 2000-4811 | A | 20000414 | | |

OS MARPAT 135:331414
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns benzo[h][1,6]naphthyridine and azepino[3,2]quinoline imino-ethers I, II, and III, and their salts and possible isomers and isomer mixts. [wherein n = 0-1; R, R' = H, halo; R1 = H, Ph optionally substituted by halo, C1-4 alkyl, or C1-4 alkyl; R2 = NR3R4 or heterocyclic group Q; R3, R4 = H, C1-4 alkyl; m, p = 0, 1, 2; (m+p) ≥ 1; R5 = H, C1-8 alkyl, C2-6 alkenyl, Ph or CH2Ph optionally substituted by halo, C1-4 alkyl, or C1-4 alkoxy]. The invention also concerns the therapeutic use of the compds., in particular as 5-HT antagonists, and as antidepressant drugs, or to treating **mnemic** disorders. Eighteen compds. were prepared as fumarate salts. For instance, etherification of 1-butyl-4-(hydroxymethyl)piperidine with 5-chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine using NaH in DMF gave 14% title compound IV, isolated as the monofumarate salt. In the forced swimming test in mice, an assay for antidepressant activity, this salt at only 1 mg/kg (i.p.) showed an effect comparable to that of imipramine at 30 mg/kg. In the abdominal constriction test in mice, a bioassay for analgesic activity, the same salt at only 0.1 mg/kg (i.p.) gave analgesic activity comparable to aspirin at 15 mg/kg. Another invention compound showed an antagonist profile at 5-HT4 receptors.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The invention concerns benzo[h][1,6]naphthyridine and azepino[3,2]quinoline imino-ethers I, II, and III, and their salts and possible isomers and isomer mixts. [wherein n = 0-1; R, R' = H, halo; R1 = H, Ph optionally substituted by halo, C1-4 alkyl, or C1-4 alkyl; R2 = NR3R4 or heterocyclic group Q; R3, R4 = H, C1-4 alkyl; m, p = 0, 1, 2; (m+p) ≥ 1; R5 = H, C1-8 alkyl, C2-6 alkenyl, Ph or CH2Ph optionally substituted by halo, C1-4 alkyl, or C1-4 alkoxy]. The invention also concerns the therapeutic use of the compds., in particular as 5-HT antagonists, and as antidepressant drugs, or to treating **mnemic** disorders. Eighteen compds. were prepared as fumarate salts. For instance, etherification of 1-butyl-4-(hydroxymethyl)piperidine with 5-chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine using NaH in DMF

gave 14% title compound IV, isolated as the monofumarate salt. In the forced swimming test in mice, an assay for antidepressant activity, this salt at only 1 mg/kg (i.p.) showed an effect comparable to that of imipramine at 30 mg/kg. In the abdominal constriction test in mice, a bioassay for analgesic activity, the same salt at only 0.1 mg/kg (i.p.) gave analgesic activity comparable to aspirin at 15 mg/kg. Another invention compound showed an antagonist profile at 5-HT4 receptors.

L1 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:118024 CAPLUS
DN 86:118024
TI Transmitter-dependent peptide synthesis in the central nervous system
AU Reichelt, K. L.; Edminson, P. D.
CS Dep. Neurochem., Univ. Psychiatr. Clin., Oslo, Norway
SO Advances in Biochemical Psychopharmacology (1976), 15(First Second Messengers - New Vistas), 211-23
CODEN: ABPYBL; ISSN: 0065-2229
DT Journal; General Review
LA English
AB A review with 52 refs., primarily on the biosynthesis of peptides by the central nervous system. The occurrence, action on individual nervous, **mnemic** and behavioral effects, and catabolism of peptides in the central nervous system are also discussed.
AB A review with 52 refs., primarily on the biosynthesis of peptides by the central nervous system. The occurrence, action on individual nervous, **mnemic** and behavioral effects, and catabolism of peptides in the central nervous system are also discussed.

L1 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1975:95779 CAPLUS
DN 82:95779
TI Morphological and biochemical basis of memory
AU Constantinidis, J.
CS Clin. Psychiatr., Univ. Geneve, Geneva, Switz.
SO Revue Medicale de Dijon (1974), 9(8), 412-13, 416-422, 424
CODEN: RMDJA9; ISSN: 0035-3647
DT Journal; General Review
LA French
AB A review with 75 refs. discussing neurotransmitters role in memory, long term memory and its cortical representation, the electrochem. of short term memory, a comparison of genetic and immunol. memories, and the morphol. structure of the **mnemic** fixation at the level of the nerve cell.
AB A review with 75 refs. discussing neurotransmitters role in memory, long term memory and its cortical representation, the electrochem. of short term memory, a comparison of genetic and immunol. memories, and the morphol. structure of the **mnemic** fixation at the level of the nerve cell.